Form PRE 14A - Other preliminary proxy statements:
SEC Accession No. 0001193125-23-291239
Filing Date
2023-12-08
Accepted
2023-12-08 08:30:50
Documents
9
Period of Report
2024-01-31

Document Format Files

Seq Description Document Type Size
1 PRE 14A d897919dpre14a.htm PRE 14A 203897
3 GRAPHIC g897919g25g25.jpg GRAPHIC 115571
4 GRAPHIC g897919g26g26.jpg GRAPHIC 117197
5 GRAPHIC g897919g27g27.jpg GRAPHIC 10995
6 GRAPHIC g897919g44a01.jpg GRAPHIC 30684
7 GRAPHIC g897919g44a02.jpg GRAPHIC 25495
8 GRAPHIC g897919g44a03.jpg GRAPHIC 24669
9 GRAPHIC g897919g44a04.jpg GRAPHIC 25945
10 GRAPHIC g897919g44a05.jpg GRAPHIC 27609
  Complete submission text file 0001193125-23-291239.txt   707313
Mailing Address 215 FIRST STREET CAMBRIDGE MA 02142
Business Address 215 FIRST STREET CAMBRIDGE MA 02142 617-299-8380
Sage Therapeutics, Inc. (Filer) CIK: 0001597553 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: PRE 14A | Act: 34 | File No.: 001-36544 | Film No.: 231473987
SIC: 2834 Pharmaceutical Preparations